Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Flo...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 845 2813

Website: www.sab.bio

Address:

777 W 41st St., Miami Beach, United States

stockboyaisle1 Aug. 14 at 5:46 PM

$SABS a lot of form 13 filings lately

0 · Reply

BioRich Aug. 10 at 9:02 PM

$SABS Looks like RA Capital doubled their already large stake in $SABS? And Blackrock just raised from a small position to a large position. Impressive for $SABS. Cheers!

0 · Reply

stockboyaisle1 Aug. 10 at 2:54 PM

$SABS https://x.com/sabbantibody/status/2086821718908109060?s=46&t=8p5PRpjghUtMnQeAza1jPg

0 · Reply

EarningsInsider Aug. 6 at 1:17 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-sab-biotherapeutics-stock/ $SABS SAB Biotherapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 1:06 PM

$SABS Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.28 up 74.31% YoY

0 · Reply

BioRich Aug. 5 at 2:30 AM

$SABS, $KYTX, $GUTS, $SGP and $TLSA continue to be my wake up and "Did we get bought?" Bios. Always seems to be the sleepers. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

Dubbyy Aug. 4 at 6:38 PM

$SABS 15% increase in one week

0 · Reply

MicsMugz Aug. 3 at 3:34 PM

$SABS $LRMR Buy

0 · Reply

Dubbyy Aug. 3 at 11:56 AM

$SABS what is goining on here why this increase

1 · Reply

LewisDaKat Jul. 30 at 7:00 PM

$SABS SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET https://marketwirenews.com/stock/sabs/news/sab-bio-to-host-second-quarter-2026-financial-result-4749300068815004.html?utm_source=stocktwits

0 · Reply

SAB Biotherapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 13 days ago

SAB Biotherapeutics Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 13 days ago

SAB Biotherapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:30 AM EDT - 13 days ago

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Jul 30, 2026, 8:30 AM EDT - 20 days ago

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

Jul 7, 2026, 8:00 AM EDT - 6 weeks ago

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

2026-06-24T11:25:10.000Z - 2 months ago

SAB Biotherapeutics initiated with an Overweight at Barclays

May 29, 2026, 8:00 AM EDT - 2 months ago

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

2026-05-22T09:15:45.000Z - 3 months ago

SAB Biotherapeutics initiated with a Buy at Citi

2026-05-20T09:05:51.000Z - 3 months ago

SAB Biotherapeutics initiated with a Buy at Jefferies

May 13, 2026, 7:00 AM EDT - 3 months ago

SAB Biotherapeutics Slides: Corporate presentation

2026-05-12T18:00:35.000Z - 3 months ago

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

May 12, 2026, 8:30 AM EDT - 3 months ago

SAB Biotherapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 8:30 AM EDT - 3 months ago

SAB Biotherapeutics Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 3 months ago

SAB Biotherapeutics Quarterly report: Q1 2026

May 12, 2026, 7:30 AM EDT - 3 months ago

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 5, 2026, 8:30 AM EDT - 3 months ago

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Apr 30, 2026, 8:00 AM EDT - 3 months ago

SAB Biotherapeutics Proxy statement: Proxy filing

2026-04-29T12:30:52.000Z - 4 months ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

EBS

Apr 22, 2026, 7:00 AM EDT - 4 months ago

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

2026-04-02T11:26:22.000Z - 4 months ago

SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

Mar 19, 2026, 4:01 PM EDT - 5 months ago

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-18T10:12:35.000Z - 5 months ago

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

Mar 17, 2026, 10:46 PM EDT - 5 months ago

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-17T21:35:16.000Z - 5 months ago

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

2026-03-17T20:05:50.000Z - 5 months ago

SAB Biotherapeutics announces common stock offering, no amount given

Mar 17, 2026, 4:01 PM EDT - 5 months ago

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-03-10T23:25:30.000Z - 5 months ago

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

2026-03-10T11:41:43.000Z - 5 months ago

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

Mar 10, 2026, 7:31 AM EDT - 5 months ago

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Mar 9, 2026, 5:16 PM EDT - 5 months ago

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 3:00 PM EDT - 5 months ago

SAB Biotherapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 5 months ago

SAB Biotherapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 5 months ago

SAB Biotherapeutics Annual report: Q4 2025

Mar 2, 2026, 9:00 AM EST - 6 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:40 AM EST - 6 months ago

SAB Biotherapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 10:30 AM EST - 6 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 15, 2026, 10:30 AM EST - 7 months ago

SAB Biotherapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

SAB Biotherapeutics Slides: Corporate presentation

2026-01-07T13:27:50.000Z - 8 months ago

SAB Biotherapeutics initiated with a Buy at UBS

2026-01-07T13:12:17.000Z - 8 months ago

SAB Biotherapeutics appoints David Zaccardelli as board chair

Jan 7, 2026, 8:00 AM EST - 8 months ago

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Jan 6, 2026, 8:00 AM EST - 8 months ago

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-30T15:15:19.000Z - 8 months ago

SAB Biotherapeutics files $300M mixed securities shelf

Dec 29, 2025, 7:00 AM EST - 8 months ago

SAB Biotherapeutics Registration statement: Registration Filing

2025-12-19T11:36:31.000Z - 8 months ago

SAB Biotherapeutics initiated with a Buy at Guggenheim

2025-12-18T13:05:56.000Z - 8 months ago

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

Dec 18, 2025, 8:00 AM EST - 8 months ago

First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

2025-12-17T13:12:49.000Z - 8 months ago

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

Dec 17, 2025, 8:00 AM EST - 8 months ago

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Dec 8, 2025, 8:00 AM EST - 9 months ago

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Dec 2, 2025, 3:50 PM EST - 9 months ago

SAB Biotherapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 14, 2025, 4:00 PM EST - 9 months ago

SAB Biotherapeutics Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 9 months ago

SAB Biotherapeutics Quarterly report: Q3 2025

Nov 13, 2025, 5:00 PM EST - 9 months ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov 12, 2025, 10:00 AM EST - 9 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 2:45 PM EST - 10 months ago

SAB Biotherapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Sep 22, 2025, 8:00 AM EDT - 11 months ago

SAB Biotherapeutics Registration statement: Registration Filing

Sep 19, 2025, 7:24 AM EDT - 11 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

Sep 3, 2025, 4:05 PM EDT - 1 year ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Sep 2, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Registration statement: Registration Filing

Aug 29, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 19, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 7, 2025, 7:30 AM EDT - 1 year ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Aug 7, 2025, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Quarterly report: Q2 2025

Jul 21, 2025, 7:30 AM EDT - 1 year ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Proxy statement: Proxy Filing

May 9, 2025, 9:00 AM EDT - 1 year ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q1 2025

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Quarterly report: Q1 2025

Mar 31, 2025, 7:32 AM EDT - 1 year ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Annual report: Q4 2024

Feb 12, 2025, 10:00 AM EST - 1 year ago

SAB Biotherapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 2:00 PM EST - 1 year ago

SAB Biotherapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 19, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Slides: Corporate Presentation

Nov 6, 2024, 5:05 PM EST - 1 year ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Earnings release: Q3 2024

Sep 13, 2024, 7:00 AM EDT - 2 years ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 9, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Press release: Study Update

Sep 9, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Slides: Study Update

Sep 4, 2024, 7:05 AM EDT - 2 years ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 2 years ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 8, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Quarterly report: Q2 2024

Aug 5, 2024, 7:30 AM EDT - 2 years ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 2 years ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 2 years ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 2 years ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 30, 2024, 8:00 AM EDT - 2 years ago

SAB Biotherapeutics Proxy statement: Proxy Filing

May 21, 2024, 7:15 AM EDT - 2 years ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Earnings release: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Quarterly report: Q1 2024

May 6, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

stockboyaisle1 Aug. 14 at 5:46 PM

$SABS a lot of form 13 filings lately

0 · Reply

BioRich Aug. 10 at 9:02 PM

$SABS Looks like RA Capital doubled their already large stake in $SABS? And Blackrock just raised from a small position to a large position. Impressive for $SABS. Cheers!

0 · Reply

stockboyaisle1 Aug. 10 at 2:54 PM

$SABS https://x.com/sabbantibody/status/2086821718908109060?s=46&t=8p5PRpjghUtMnQeAza1jPg

0 · Reply

EarningsInsider Aug. 6 at 1:17 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-sab-biotherapeutics-stock/ $SABS SAB Biotherapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 1:06 PM

$SABS Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.28 up 74.31% YoY

0 · Reply

BioRich Aug. 5 at 2:30 AM

1 · Reply

Dubbyy Aug. 4 at 6:38 PM

$SABS 15% increase in one week

0 · Reply

MicsMugz Aug. 3 at 3:34 PM

$SABS $LRMR Buy

0 · Reply

Dubbyy Aug. 3 at 11:56 AM

$SABS what is goining on here why this increase

1 · Reply

LewisDaKat Jul. 30 at 7:00 PM

0 · Reply

DDiamond_Handz Jul. 30 at 5:41 PM

$SABS 10$ eoy

0 · Reply

JTebow_CWS Jul. 30 at 11:47 AM

$SABS Institutional ownership is up to 90%. Loaded the boat.

0 · Reply

Orlandotrader Jul. 27 at 5:34 PM

$SABS This one is just marking time. Results 2027. No one will commit early in Bio Tech. Patience and load in lower 3$ Range.

0 · Reply

high_tech_texan Jul. 25 at 11:51 AM

$SABS These two positions are still open (from a couple of week ago): * Vice President Quality Assurance * Senior Research Associate 2, Bioanalytical Assays These TEN new job openings have just been added: * Clinical Sample Manager * Clinical Trial Manager, Immunology * Executive Director, Pharmacovigilance (PV) * Quality Systems Specialist * Research Associate 1, Antigen Production * Senior Quality Assurance Specialist * Senior Training Manager, Quality Assurance * Sr. Director, Medical Writing – Biologics * Vice President Manufacturing * Vice President Regulatory Affairs

2 · Reply

BioRich Jul. 21 at 4:42 PM

$FDMT continues to get attention. New to many so take a look and let me know your thoughts. $IBRX, $SMMT $SABS and $VKTX also leading the first half of the day. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more( money. Cheers!

0 · Reply

stockboyaisle1 Jul. 21 at 1:24 PM

$SABS This guy does an amazing job of explaining 142: https://x.com/anthonystaj/status/2033274287415517322/video/1?s=46

0 · Reply

gobio Jul. 20 at 3:47 PM

$SABS https://www.biospace.com/drug-development/type-1-diabetes-pipeline-making-remarkable-progress-toward-insulin-independence?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsenc=p2ANqtz-_nghluMigmY8U5jxGxzp0jn2DdVQ_oDx1-jDxUV-ZGjMkkjwTqFy8ObrILtJCGpqtxYuL9IITVpmCFmJ2k0O9Rns9EEQ&_hsmi=429206667&utm_content=429206667&utm_source=hs_email

0 · Reply

GlobalMarketBulletin Jul. 18 at 9:06 AM

$SABS SAB Biotherapeutics Inc. (SABS) has a $13 analyst target and a promising type 1 diabetes therapy. Could this biotech stock under $5 deliver massive upside? https://globalmarketbulletin.com/is-sab-biotherapeutics-sabs-an-undervalued-biotech-stock-ready-to-take-off/

0 · Reply

GlobalMarketBulletin Jul. 18 at 8:25 AM

$ATAI $LRMR $SABS $VSTM $SOC Wall Street sees triple-digit upside in several of these stocks under $10. Discover the biotech, healthcare, energy, and cryptocurrency names investors are closely watching. https://globalmarketbulletin.com/10-stocks-under-10-analysts-believe-could-soar-200/

2 · Reply

Dubbyy Jul. 17 at 3:39 PM

$SABS good long here

1 · Reply

Nicks_pics Jul. 9 at 3:17 PM

$SABS How is the SABSW volume 222,627 and it’s only moved .0001? There have been no buyers and sellers for those for over a year. 🤷‍♂️

1 · Reply

DDiamond_Handz Jul. 7 at 5:22 PM

$SABS mirroring $SPY agian...

0 · Reply

Market Cap	343.02M
Revenue (ttm)	0.00
Net Income (ttm)	13.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	351,300
Avg Vol	752,636
Day's Range	N/A - N/A
Shares Out	90.99M
Stochastic %K	53%
Beta	0.53
Analysts	Strong Sell
Price Target	$11.64